October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 21, 2025

After the Light: Searching for Support

Most near-death experiencers sought help to process their episode, and validation made a difference—those met with understanding rated support as more effective; deeper experiences drove help-seeking, while stigma and access issues often stood in the way.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

HHS Memo: Fringe Finds a Footing

From wheat fields to Washington: a decades-old fear about skies and 'sprays' rises again, colliding with science, social media, and the machinery of federal policymaking.

KFF Health News

October 16, 2025

Depression Risk Rises Among Gabapentin Users

Gabapentin is most strongly associated with depression among women, lower-income patients, and those who sleep fewer than 7 hours per night.

Conexiant

October 13, 2025

Blood Test Classified ME/CFS With 96% Accuracy, Study Shows

Epigenetic blood markers reveal immune activity patterns in patients with ME/CFS.

Conexiant

October 10, 2025

Panel Finalizes 6 Cannabis Competencies For US Med Schools

New framework guides medical schools in teaching evidence-based cannabis education.

Conexiant

October 06, 2025

Gabapentin Adds No Post-Surgery Recovery Benefit, Study Shows

Gabapentin use in major surgery patients shows no improvement in pain or life quality.

Conexiant

October 02, 2025

Distal vs Shaft Tibia Fractures in Children

Open distal tibia fractures in pediatric patients are more severe than shaft fractures.

Conexiant